New CMC Process R&D center will add peptide and oligo-intermediate capabilities, expand analytical and formulation labs and target completion by September 2026.
Sai Life Sciences plans to build a 100,000-sq-ft CMC Process R&D center at its integrated R&D campus in Hyderabad, aiming to double its process R&D capacity by September 2026. The project adds dedicated labs for peptides and oligonucleotide intermediates and linkers, a 25,000-sq-ft centralized analytical lab, formulation development, early-phase clinical supply capabilities, and a kilo lab for early clinical manufacturing. The facility is designed for containment to OEL 4, or 1 microgram per cubic meter, and as a green building, according to the company.
“As our partners seek greater speed, flexibility and scientific depth, we are scaling our capabilities,” said CEO and Managing Director Krishna Kanumuri. The site will support both full-time equivalent and dedicated project capacity engagement models to serve programs from early development through late-stage CMC.
Peptide and oligo supply chains remain tight as modality pipelines expand. Adding specialized labs, higher-throughput fume-hood capacity (140 hoods) and larger centralized analytics should help compress development timelines for innovators working with complex peptide therapeutics and emerging modalities.
Filed Under: Drug Discovery and Development
